

Faculty of Health Sciences

Basal Statistik

Kategorisk outcome. Tabeller.

Lene Theil Skovgaard

16. september 2019



Et par tabeller

hentet fra artiklen:

Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study.


(P. B. Hansen & M. Penkowa, Support Care Cancer)



Febril Neutropenia

Sammenligning af Bismuth og Placebo:

Antallene er i procent



Der er 10 i placebo-gruppen og 13 i Bismuth-gruppen:

Fig. 2: Febrile neutropenia in multiple myeloma patients treated with placebo (n = 10) or bismuth (n = 13).

a) Incidence of febrile neutropenia in patients treated with placebo (40%) relative to bismuth (23%) ($p = 0.0005$).

Febril Neutropenia

Lad os checke den sammenligning:

Table of treat by status

treat	status		
Frequency	Expected		
Row Pct	rask	syg	Total
-----+-----+-----+			
bismuth	10	3	13
	9.0435	3.9565	
	76.92	23.08	
-----+-----+-----+			
placebo	6	4	10
	6.9565	3.0435	
	60.00	40.00	
-----+-----+-----+			
Total	16	7	23

Statistics for Table of treat by status

Statistic	DF	Value	Prob

Chi-Square	1	0.7646	0.3819
Likelihood Ratio Chi-Square	1	0.7616	0.3828
Continuity Adj. Chi-Square	1	0.1742	0.6764

WARNING: 50% of the cells have expected counts less than 5.

Chi-Square may not be a valid test.


Fisher's Exact Test

Two-sided Pr <= P	0.6500
-------------------	--------

Sample Size = 23



Kønsforskel, opdelt efter behandling



d) Gender differences in the incidence of febrile neutropenia in placebo- and bismuth-treated groups. The incidence rates were 42% for males versus 33% for females treated with placebo ($p = 0.04$), while in bismuth-treated patients, 14% of males had febrile neutropenia while the female incidence remained at 33% ($p = 0.00005$). The figure shows data from placebo-treated females ($n = 3$), placebo-treated males, ($n = 7$), bismuth-treated females ($n = 6$) and bismuth-treated males ($n = 7$). As shown, only males benefit from bismuth in terms of avoiding febrile neutropenia

Tabeller, opdelt efter behandling

Placebo

	Status		Total
	Rask	Syg	
Kvinder	2	1	3
Mænd	4	3	7
Total	6	4	10

$P=1!!!$

Bismuth

	Status		Total
	Rask	Syg	
Kvinder	4	2	6
Mænd	6	1	7
Total	10	3	13

$P=0.56$



Tabeller, opdelt efter køn

Kvinder

	Status		Total
	Rask	Syg	
Bismuth	4	2	6
Placebo	2	1	3
Total	6	3	9

$P=1!!!$

Mænd

	Status		Total
	Rask	Syg	
Bismuth	6	1	7
Placebo	4	3	7
Total	10	4	14

$P=0.56$